Rituximab treats myasthenia gravis patients with anti-MuSK antibodies
Rituximab effectively treated most myasthenia gravis (MG) patients who were positive for antibodies against muscle-specific tyrosine kinase (MuSK), a small study shows. The therapy eased MG symptoms and led to gains in measures of clinical severity. It also enabled patients to reduce or stop taking other medications,…